Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sofosbuvir/Velpatasvir (SOF/VEL) Clear all
Recruiting Not applicable Interventional

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

NCT05653232
View directory record Official record
Conditions
HCV
Interventions
Prophylaxis (P2W), Transmit and Treat (T&T)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

NCT01909804
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

NCT02378961
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

NCT02346721
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

NCT03022981
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

NCT02300103
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
San Diego, California • San Marcos, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 4 Interventional Results available

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013
View directory record Official record
Conditions
HCV Coinfection, Liver Disease, HIV
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 1, 2026, 10:09 PM EDT
Terminated No phase listed Observational

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 1, 2026, 10:09 PM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

NCT02201953
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Not listed Phase 4 Interventional

Curing HCV in Incarcerated Patients

NCT03018353
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Patients receiving Sof/Vel (Epclusa) and Navigation services
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

NCT03118843
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Rialto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

NCT02536313
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

NCT02220998
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
50
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

NCT02480712
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

NCT03501550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
CDI-31244, SOF/VEL
Drug
Lead sponsor
Cocrystal Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

NCT01858766
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
50
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

NCT02994056
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Tampa, Florida • Chicago, Illinois • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 1, 2026, 10:09 PM EDT
Active, not recruiting Phase 3 Interventional

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264
View directory record Official record
Conditions
HEPATITIS C VIRUS CHRONIC INFECTION
Interventions
Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
96
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 1, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607735
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 1, 2026, 10:09 PM EDT